GlassScriptPhysician profile
Christopher K Boschee
NPI 1295992154
$657.10
in general payments reported to CMS, 2019-2025
20 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $80.81 · 2021: $51.86 · 2022: $27.76 · 2023: $26.73 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $131.98 | 2019-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $122.39 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.06 | 2019-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.23 | 2025 | Caplyta |
| Lilly USA, LLC | $32.29 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $31.01 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $30.36 | 2019 | |
| Abbvie INC. | $26.13 | 2025 | |
| Grifols USA, LLC | $25.83 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $22.44 | 2019 | |
| Dexcom, INC. | $17.96 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $17.64 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $15.67 | 2020 | |
| Exact Sciences Corporation | $14.96 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $14.03 | 2023 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.64 | 2019 | |
| Gilead Sciences, INC. | $12.68 | 2019 | |
| Merck Sharp & Dohme LLC | $11.99 | 2020 | |
| Daiichi Sankyo INC. | $11.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Boschee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.